Is Etanercept 25 mg Once Weekly as Effective as 50 mg at Maintaining Response in Patients with Ankylosing Spondylitis? A Randomized Control Trial

Max Yates, Louise E Hamilton, Frances Elender, Loretta Dean, Helen Doll, Alex J. MacGregor, Joegi Thomas, Karl Gaffney (Lead Author)

Research output: Contribution to journalArticlepeer-review

29 Citations (Scopus)
5 Downloads (Pure)

Abstract

To investigate, in a pilot randomized controlled trial, whether etanercept (ETN) 25 mg once weekly is effective at maintaining a clinical response in patients with ankylosing spondylitis (AS) who have responded to the standard 50 mg dose.
Original languageEnglish
Pages (from-to)1177-1185
Number of pages9
JournalJournal of Rheumatology
Volume42
Issue number7
Early online date1 Jun 2015
DOIs
Publication statusPublished - Jul 2015

Keywords

  • Ankylosing Spondylitis
  • Anti-tumor necrosis factor therapy
  • etanercept
  • randomized control trial

Cite this